Sophion webinar recording: New compounds for pain and epilepsy: sodium and potassium channel gating modifiers from Qube 384 screens
Last week, guest speaker Bruce Bean from Harvard Medical School together with Sophion’s Mads P. G. Korsgaard and hosted by Sophion’s Damian Bell, led a webinar showcasing the power of automated patch clamp technology to identify and characterize gating modifiers of voltage-dependent ion channels.
Mads P. G. Korsgaard opened by introducing the Qube 384 as a tool for drug discovery, followed by Bruce Bean, who explained how the Bean Lab at Harvard Medical School is leveraging the Qube 384 platform to both characterize the mechanisms of action of known drug classes, such as Nav1.8 inhibitors and Kv7 enhancers, and to screen for novel compounds targeting underexplored ion channel families, including Kv1, Kv2, and Kv3, which have received limited attention in drug development.
In this webinar, you can learn how high throughput automated patch clamp can be used for ensuring precise and efficient screening of sodium and potassium channel gating modifiers. Tailored for innovators in biotech and pharma, we offer new perspectives on targeting underexplored ion channels for therapeutic development.